Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
78 hedge funds and large institutions have $183M invested in Melinta Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
35% less call options, than puts
Call options by funds: $1.85M | Put options by funds: $2.84M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.6M |
| 2 |
BlackRock
New York
|
+$8.95M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.73M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$6.37M |
| 5 |
Millennium Management
New York
|
+$4.13M |
Top Sellers
MLNT Hedge Fund Activity: Q4 2017 in Review
78 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q4 2017, worth a combined $183M.
Buyers outnumbered sellers: 78 funds opened new MLNT positions and 0 closed out — a net gain of 78 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $14.6M.
- 78 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $183M of Melinta Therapeutics, Inc. Common Stock stock for Q4 2017.
- 78 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q4 2017 and 0 closed out, a net change of +78 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q4 2017 was Fidelity Investments, an estimated $14.6M added.
Based on aggregated 13F filings for Q4 2017.